| Nov 1 |
Loss-Making Avadel Pharmaceuticals plc (NASDAQ:AVDL) Expected To Breakeven In The Medium-Term
|
| Oct 31 |
Avadel soars after court rules in favor of FDA in Lumryz case with Jazz Pharma
|
| Oct 31 |
Avadel Pharmaceuticals Announces Favorable Ruling in Administrative Procedure Act Litigation
|
| Oct 31 |
Why Carvana Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket
|
| Oct 24 |
Avadel Pharmaceuticals and nference Announce Publication of Real-World Data in Sleep Advances
|
| Oct 18 |
Avadel wins FDA approval for narcolepsy drug Lumryz in children
|
| Oct 18 |
Avadel Obtains FDA Nod for Label Expansion of Narcolepsy Drug Lumryz
|
| Oct 17 |
Avadel Pharmaceuticals Announces FDA Approval of LUMRYZ™ (sodium oxybate) Extended-Release Oral Suspension (CIII) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Patients 7 Years of Age and Older with Narcolepsy
|
| Oct 9 |
Avadel Pharmaceuticals PLC (AVDL) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ...
|
| Sep 25 |
Avadel Pharmaceuticals Announces Publication of Data Highlighting Efficacy of LUMRYZ™ (sodium oxybate) Extended-Release Oral Suspension in Improving Narcolepsy Symptoms Regardless of Concomitant Use of an Alerting Agent
|
